Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1809040
Max Phase: Preclinical
Molecular Formula: C32H37N5O2
Molecular Weight: 523.68
Molecule Type: Small molecule
Associated Items:
ID: ALA1809040
Max Phase: Preclinical
Molecular Formula: C32H37N5O2
Molecular Weight: 523.68
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C([C@@H]1C=C2c3cccc4c3c(cn4CCN3CCCC3)C[C@H]2N(C(=O)Nc2ccccc2)C1)N1CCCC1
Standard InChI: InChI=1S/C32H37N5O2/c38-31(35-15-6-7-16-35)24-19-27-26-11-8-12-28-30(26)23(21-36(28)18-17-34-13-4-5-14-34)20-29(27)37(22-24)32(39)33-25-9-2-1-3-10-25/h1-3,8-12,19,21,24,29H,4-7,13-18,20,22H2,(H,33,39)/t24-,29-/m1/s1
Standard InChI Key: ODGLLEQMXCBDJJ-FUFSCUOVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 523.68 | Molecular Weight (Monoisotopic): 523.2947 | AlogP: 4.83 | #Rotatable Bonds: 5 |
Polar Surface Area: 60.82 | Molecular Species: BASE | HBA: 4 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 7 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 13.36 | CX Basic pKa: 9.50 | CX LogP: 3.76 | CX LogD: 1.67 |
Aromatic Rings: 3 | Heavy Atoms: 39 | QED Weighted: 0.52 | Np Likeness Score: -0.68 |
1. Thoma G, Baenteli R, Lewis I, Jones D, Kovarik J, Streiff MB, Zerwes HG.. (2011) Special ergolines efficiently inhibit the chemokine receptor CXCR3 in blood., 21 (16): [PMID:21764306] [10.1016/j.bmcl.2011.06.070] |
Source(1):